Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Enzalutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer (KEYNOTE-991)
NCT04934722Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in prostate cancer (PCa), sponsored by Merck & Co.. Started May 2021; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04934722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934722.